Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 2/20 | 0.31 |
| ▸ | PDE8B | O95263 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166234 | 0.81 | LRRK2 (0.37) | LRRK2KRASDRD2DRD3KIF11 | |
| SCHEMBL28182364 | 0.77 | LRRK2 (0.39) | LRRK2KRAS | |
| SCHEMBL23497183 | 0.76 | KRAS (0.47) | LRRK2KRASDRD4 | |
| SCHEMBL19002452 | 0.76 | KRAS (0.45) | LRRK2KRASDRD4 | |
| SCHEMBL18997551 | 0.76 | KRAS (0.45) | LRRK2KRASDRD4 | |
| SCHEMBL28860098 | 0.74 | DRD4 (0.34) | LRRK2DRD2DRD3SLC6A4HRH3 | |
| SCHEMBL12539252 | 0.71 | DRD4 (0.43) | DRD4 | |
| SCHEMBL2050325 | 0.71 | KIF11 (0.40) | LRRK2KIF11 | |
| SCHEMBL27373358 | 0.71 | ELOVL1 (0.44) | LRRK2CCNT1CDK9SLC6A4HRH3 | |
| SCHEMBL27766777 | 0.70 | KIF11 (0.37) | LRRK2HRH3KCNH2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | LRRK2 1/4885KRAS 29/4885CCNT1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.